Alpha Cancer Technologies holds exclusive worldwide rights to recombinant human alpha fetoprotein (AFP) and to the inventions built on it.
The ACT-903 combination. ACT’s 2022 patent application covers the three-component combination behind its lead oncology program: recombinant human AFP (ACT-101), a glutathione-sensitive linker created for ACT, and a proprietary maytansine payload.
- Europe: the 2022 application (EP 4373844) is pending, with coverage, if granted, to 2042 and beyond.
- Pending: applications in the United States, Canada, China, and India.
The wider estate. ACT’s position also rests on the AFP patent estate in-licensed from Merrimack Pharmaceuticals — the program Merrimack developed through Phase I and II studies of ACT-101 — and on the manufacturing estate around the E. coli cell line, developed by absci, that produces ACT-101.